Specialty Pharmacy

African Americans have the most severe burden of HIV in the United States.

Top news of the week in oncology and cancer drug development.

Promising data on pediatric relapsed/refractory acute lymphoblastic leukemia to be presented.

Researchers have identified an antibody that can neutralize 98% of HIV strains, and may serve as a potential candidate for future HIV treatment and prevention.

Cognitive and physical fitness may play a role in the development of ALS.

Top news of the week on Specialty Pharmacy Times.

Targeting TAZ can essentially stop fibrosis and may provide future treatment options for patients with nonalcoholic steatohepatitis.

Top news of the day from across the health care landscape.

Patients with rheumatoid arthritis want a fast-acting, orally administered treatment for their symptoms.

Viral loads were reduced in SIV-infected rhesus monkeys given an experimental vaccine in combination with an immune stimulant.

A simple questionnaire and testing can help identify more patients with chronic obstructive pulmonary disease.

Top news of the day from across the health care landscape.

Baricitinib significantly improved patient-reported outcomes in individuals with RA.

New drugs for psoriatic arthritis discussed during a session at the ACR/ARHP conference.

At the Annual Meeting of the American College of Rheumatology in Washington, DC, several experts presented their progress in harnessing technology to help teenagers and young adults manage their juvenile arthritis.

Study compares the safety and efficacy of sarilumab with adalimumab in patients who cannot tolerate methotrexate.

Wayne Grau, vice president of Legislative Affairs at Managed Health Care Associates, discusses the implications of the Medicare Home Infusion Site of Care Act for specialty pharmacy stakeholders.

Reduced reimbursements, Medicare Part D, and the Affordable Care Act have stimulated pharmacies to offer a broader palette of services.

Combination immunotherapy more successful in treating advanced skin cancer.

An ACR session focused on the Sunshine Act and health care transparency.

Baricitinib is a once-daily oral selective JAK1 and JAK2 inhibitor for the treatment of autoimmune and inflammatory diseases.

Two pilot studies are transplanting infected kidneys into patients and then treating them with curative hepatitis C medications.

Sarilumab shows promise on circulating biomarkers of bone and joint destruction in patients with rheumatoid arthritis who had shown an inadequate response to methotrexate.

Patients with rheumatoid arthritis who demonstrate a less-than-adequate response to a tumor necrosis factor inhibitor can be treated with another disease-modifying antirheumatic drug.

Regulatory perspectives presented at ACR on biosimilars entering the market convey the importance of crafting antibodies to our own purposes.

Low health literacy, financial instability, and lack of social support promote poor adherence.

Top news of the day from across the health care landscape.

Zepatier shows promise across genotypes 1 and 4, even among patients administered opioid agonist therapy.